Ignite Creation Date:
2024-05-05 @ 4:56 PM
Last Modification Date:
2024-10-26 @ 9:26 AM
Study NCT ID:
NCT00354653
Status:
COMPLETED
Last Update Posted:
2020-03-03
First Post:
2006-07-19
Brief Title:
A Trial To Study The Effect Of Lamivudine In Adult Patients Who Suffer From Chronic Hepatitis B Alone
Sponsor:
ViiV Healthcare
Organization:
ViiV Healthcare
Study Overview
Official Title:
AN OPEN STUDY OF LAMIVUDINE TREATMENT IN ADULT HBeAg NEGATIVE Presumed Pre-core Mutant CHRONIC HEPATITIS B PATIENTS IN IRAN
Status:
COMPLETED
Status Verified Date:
2020-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The efficacy of lamivudine in Hepatitis Be Antigen HBeAg positive Asian patients of chronic hepatitis has been well establishedThe evidence in HBeAg negative patients is limited Limited sustained response was observed post-treatment following a one year treatment period Whether these results can be applied to patients in Iran is uncertain This study is therefore intended to further assess the efficacy profile after two years of open treatment in the adult Iranian population
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None